Transcriptomics

Dataset Information

0

Secondary proteasome inhibitor carfilzomib resistant myeloma cell lines


ABSTRACT: Modulation of the activity of the ubiquitin-proteasome pathway with the proteasome inhibitor (PI) is an established component of therapy for plasma cell disorders. However, resistance emerges and the mechanism is incompletely understood. We generated carfilzomib-resistant (CR) myeloma cell lines by exposing drug-naive ANBL-6, KAS-6/1, U266, and OPM-2 cells to increasing concentrations of carfilzomib and then performed gene expression profiling (GEP) to identify prominent changes compared to their vehicle-treated counterparts, followed by exploration of the mechanism(s) of proteasome inhibitor resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE62237 | GEO | 2016/10/09

SECONDARY ACCESSION(S): PRJNA263564

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-09-28 | PXD020906 | Pride
2020-09-28 | PXD021001 | Pride
2024-07-12 | GSE268000 | GEO
2024-07-12 | GSE268242 | GEO
2015-07-09 | E-GEOD-69078 | biostudies-arrayexpress
2023-07-01 | E-MTAB-11028 | biostudies-arrayexpress
2016-09-13 | GSE78069 | GEO
2023-08-21 | GSE227899 | GEO
2013-07-02 | E-GEOD-41929 | biostudies-arrayexpress
2015-07-09 | GSE69078 | GEO